ArticleRheumatic diseases clinics of North America2014
The kidney biopsy in lupus nephritis: is it still relevant?
Article in Rheumatic diseases clinics of North America, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 45 citations in OpenAlex.
- Factors associated with clinically significant nephritis in systemic lupus erythematosus patients who present with glomerular hematuria: a cross-sectional study.Rheumatology international · 2026Article
- Extracellular vesicles and their role in Lupus Nephritis: A scoping review.Journal of translational autoimmunity · 2026Review
- Evaluation of clinical, histological and biomarker response after initial therapy of lupus nephritis.Lupus science & medicine · 2026Article
- Podocyte extracellular vesicles and immune mediators as urinary biomarkers in active lupus nephritis.Scientific reports · 2025Article
- Immunological Avalanches in Renal Immune Diseases.Biomedicines · 2025Review
- Urine Extracellular Vesicles Size Subsets as Lupus Nephritis Biomarkers.Diagnostics (Basel, Switzerland) · 2024Article
- Microvascular Density Analysis of Patients with Inactive Systemic Lupus Erythematosus-A Two-Year Follow-Up Optical Coherence Tomography Angiography Study.Journal of clinical medicine · 2024Article
- Kidney Biopsy in Management of Lupus Nephritis: A Case-Based Narrative Review.Kidney medicine · 2024Review
- An interpretable machine learning pipeline based on transcriptomics predicts phenotypes of lupus patients.iScience · 2023Article
- Lupus nephropathy beyond immunosuppression: Searching for nephro and cardioprotection.Frontiers in nephrology · 2023Review
- Clinical and Immunological Biomarkers for Systemic Lupus Erythematosus.Biomolecules · 2021Review
- Accelerating Medicines Partnership: Organizational Structure and Preliminary Data From the Phase 1 Studies of Lupus Nephritis.Arthritis care & research · 2020Review
- [Lupus nephritis].Zeitschrift fur Rheumatologie · 2018Article
- A Predictive Model for Estimation Risk of Proliferative Lupus Nephritis.Chinese medical journal · 2018Article
- Histologic versus clinical remission in proliferative lupus nephritis.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2017Article
- Redefining lupus nephritis: clinical implications of pathophysiologic subtypes.Nature reviews. Nephrology · 2017Review
- The value of repeat biopsy in lupus nephritis flares.Medicine · 2017Review
- Long-term Outcome of Lupus Nephritis Class II in Argentine Patients: An Open Retrospective Analysis.Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases · 2016Article
- What is damaging the kidney in lupus nephritis?Nature reviews. Rheumatology · 2016Review
- Validation of the Lupus Nephritis Clinical Indices in Childhood-Onset Systemic Lupus Erythematosus.Arthritis care & research · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
The kidney biopsy is the standard of care for diagnosis of lupus nephritis and remains necessary to ensure accurate diagnosis and guide treatment. Repeat biopsy should be considered when therapy modifications are necessary, as in cases with incomplete or no response, or when stopping therapy for those in remission. There are several promising biomarkers of kidney disorders; however, these markers need to be validated in a prospective clinical trial before being applied clinically. Molecular analysis may provide the information presently lacking from current evaluation of kidney disorders and may better inform on prognosis and treatment considerations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.